FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid

FluxMPS™ DCP-RPMIGH-QB1X is a Microfluidics Suitable, ultra-filtered RPMI 1640 formulation engineered for organ-on-a-chip (OoC) and microphysiological system (MPS) platforms. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• Quadruple-stage filtration (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final pore size for microfluidic-scale purity
• HEPES-buffered (25 mM) formulation; bicarbonate-free, reducing dependence on CO₂ incubation — validate empirically per cell line
• High glucose (4500 mg/L) with 110 mg/L sodium pyruvate for robust energy metabolism support
• Formulated without L-Glutamine — add fresh L-glutamine or a stable dipeptide substitute at time of use
• Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85>)
• Manufactured under an ISO 13485:2016 quality management system with full lot traceability
• 39 verified ingredients per lot across inorganic salts, amino acids, vitamins and other components, with CAS traceability
• pH, glucose, HEPES, salts and nutrient composition available on request — contact support@diagnocine.com

Engineered where standard media fails

Conventional 0.22 µm–filtered media passes mycoplasma, subvisible particulates, and endotoxin fragments that confound cell assays run on microfluidic-scale platforms.

Quadruple-stage filtration system

Four serial filtration stages, run as two dedicated prefilter + final-filter pairs, reaching a final 0.04 µm polish under aseptic conditions.

1. 1

   0.1 µm Prefiltration I

   Removes large aggregates, cell debris and protein precipitates; protects the first 0.04 µm cartridge from fouling and extends its service life.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass through a standard 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm cartridge; provides 0.1 µm mycoplasma-retentive filtration (not tested per lot).

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter prior to aseptic fill & finish under ISO Class 5 conditions; final product QC release gate.

OoC and MPS Applications

FluxMPS™ DCP-RPMIGH-QB1X delivers Microfluidics Suitable purity for organ-on-a-chip, microfluidic and lymphocyte/immune-cell culture applications.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) MPS Grade ultra nano-filtered variant of this formulation is available on request for automated bioreactors and robotic perfusion systems.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates that foul automated systems
• Valve & Sensor Protection: Reduces micro-fouling in automated perfusion and recirculation systems
• Extended Perfusion Stability: Consistent nutrient delivery over long-duration culture runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.

Analytical release specifications

Every lot released against the full specification matrix. Certificate of Analysis available: support@diagnocine.com.

Full composition (mg/L)

RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid — 39 ingredients verified per lot with CAS numbers for full raw-material traceability.

ISO 13485 Manufacturing & Compliance

Every batch of FluxMPS™ DCP-RPMIGH-QB1X is manufactured under a certified ISO 13485:2016 QMS with full lot traceability and multi-parameter QC release testing.

How DCP-RPMIGH-QB1X compares

FluxMPS™ versus conventional 0.22 µm filtered media for OoC and MPS applications.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-RPMIGH-QB1X and its use in OoC and MPS applications.

Supporting literature

Curated peer-reviewed references relevant to OoC/MPS applications and FluxMPS™ ultra-filtered cell culture media.

1. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nature Biotechnology. 2014;32(8):760–772.doi:10.1038/nbt.2989
2. Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in biomedical research. Nature. 2014;507(7491):181–189.doi:10.1038/nature13118
3. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
4. Ingber DE. Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? Advanced Science. 2020;7(22):2002162.doi:10.1002/advs.202002162
5. Maoz BM, et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic landscape of brain disease. Nature Biotechnology. 2018;36:865–874.doi:10.1038/nbt.4226
6. Moore GE, Gerner RE, Franklin HA. Culture of normal human leukocytes. JAMA. 1967;199(8):519–524.doi:10.1001/jama.1967.03120080053007
7. Luni C, Serena E, Elvassore N. Human-on-chip for therapy development and fundamental science. Current Opinion in Biotechnology. 2014;25:45–50.doi:10.1016/j.copbio.2013.08.015
8. Erickson KA, Bhansali S. Mycoplasma contamination in cell cultures: a survey of incidence and approaches to prevention. Journal of the Association for Laboratory Automation. 2012;17(5):346–354.doi:10.1177/2211068212456089
9. van Duinen V, et al. Microfluidic 3D cell culture: from tools to tissue models. Current Opinion in Biotechnology. 2015;35:118–126.doi:10.1016/j.copbio.2015.05.002
10. Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. Journal of Physiology. 2021;599(6):1745–1757.doi:10.1113/JP278810